Switching from a vitamin K antagonist to a NOAC

被引：2
|
作者：
Senoo, Keitaro [1 ]
Lip, Gregory Y. H. [1 ,2 ]
机构：
[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
[2] Aalborg Univ, Aalborg Thrombosis Res Unit, Dept Clin Med, Aalborg, Denmark
来源：
LANCET HAEMATOLOGY | 2015年 / 2卷 / 04期
关键词：
ATRIAL-FIBRILLATION; DABIGATRAN; ANTICOAGULATION; PREVENTION; WARFARIN; STROKE; EVENTS;
D O I：
10.1016/S2352-3026(15)00041-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E132 / E133
页数：2
相关论文
共 50 条
  • [1] Non-vitamin K oral antagonist (NOAC) compared to vitamin K antagonist (VKA) in left ventricular thrombus
    Al-Kaf, Fahmi
    Al Basiri, Saleh
    Al Ash'hab, Yasser
    Otain, Mohammad
    Al Askary, Hafed
    Al Khushail, Abdullah
    Robert, Asirvatham Alwin
    Al Fagih, Ahmed
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2024, 13 (06) : 2485 - 2490
  • [2] Choosing between a NOAC or a vitamin K antagonist: an approach based on risk stratification
    DeMaria, Anthony
    Cotter, Bruno
    EUROPEAN HEART JOURNAL, 2017, 38 (12) : 897 - 898
  • [3] Non-vitamin K antagonist oral anticoagulant (NOAC) - what was new in 2017?
    Szymanski, Filip M.
    KARDIOLOGIA POLSKA, 2017, 75 : 65 - 70
  • [4] Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry
    Beyer-Westendorf, Jan
    Gelbricht, Vera
    Foerster, Kati
    Ebertz, Franziska
    Roellig, Denise
    Schreier, Thomas
    Tittl, Luise
    Thieme, Christoph
    Haensel, Ulrike
    Koehler, Christina
    Werth, Sebastian
    Kuhlisch, Eberhard
    Stange, Thoralf
    Roeder, Ingolf
    Weiss, Norbert
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (04) : 908 - 917
  • [5] The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation
    Vinding, Naja Emborg
    Bonde, Anders Nissen
    Rorth, Rasmus
    Lamberts, Morten
    Olesen, Jonas Bjerring
    Gislason, Gunnar Hilmar
    Torp-Pedersen, Christian
    Kober, Lars
    Fosbol, Emit Loldrup
    EUROPACE, 2019, 21 (04): : 572 - 579
  • [6] Oral anticoagulation in atrial fibrillation: differential therapy with non vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA)
    Sucker C.
    Litmathe J.
    Berthold H.K.
    MMW - Fortschritte der Medizin, 2019, 161 (Suppl 6) : 15 - 23
  • [7] Switching from vitamin K antagonist to dabigatran in atrial fibrillation: a differences according to dose
    Vinding, Naja Emborg
    Staerk, Laila
    Gislason, Gunnar Hilmar
    Torp-Pedersen, Christian
    Bonde, Anders Nissen
    Rorth, Rasmus
    Lee, Christina J. Y.
    Olesen, Jonas Bjerring
    Kober, Lars
    Fosbol, Emil Loldrup
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (01) : 20 - 30
  • [8] SSRI co-medication with NOAC or vitamin K antagonist does not increase hospitalization for bleeding events
    Rezaei, S. Sheikh
    Mittlboeck, M.
    Reichardt, B.
    Wolzt, M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 : 92 - 92
  • [9] 'Real world' use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry
    Eikelboom, John W.
    Weitz, Jeffrey I.
    THROMBOSIS AND HAEMOSTASIS, 2015, 113 (06) : 1159 - 1161
  • [10] Management implications associated with switching from vitamin K antagonist anticoagulants to direct oral anticoagulants
    Pia-Morandeira, Agustin
    Cinza-Sanjurjo, Sergio
    Portela-Romero, Manuel
    REVISTA ESPANOLA DE CARDIOLOGIA, 2022, 75 (04): : 345 - 347
12345